Abstract
We have previously described enhanced human breast cancer cell proliferation and mouse mammary tumor growth induced by α2-adrenergic agonists, associated with α2-adrenoceptor (α2-AR) expression in epithelial cells. The aim of the present work was to assess if stromal fibroblasts can contribute to this effect. α2-AR expression was assessed by immunocytochemistry and immunohistochemistry, cell proliferation by [3H]- Thymidine incorporation and tumor growth by measuring with caliper. All tested mouse and human fibroblasts expressed at least two α2-AR subtypes and α2-adrenergic agonists enhanced fibroblast proliferation. In vivo, the α2-adrenergic agonist clonidine significantly enhanced tumor growth. The α2- adrenergic antagonist rauwolscine reversed this effect, but when administered alone, significantly inhibited tumor growth. Clonidine significantly stimulated cell proliferation in the epithelial-enriched fraction, the cancer associated fibroblastenriched fraction and the co-culture of both fractions in primary cultures from both tumors (IBH-4 and IBH-6). Rauwolscine reversed clonidine stimulation in every fraction. However, when incubated alone, the inhibitory effect was observed in fractions from IBH-4 tumors but not from IBH-6 tumors. These experiments show that fibroblasts from tumor stroma are also influenced by α2-adrenergic compounds through the α2-ARs expressed in these cells. Moreover, the α2-adrenergic antagonist rauwolscine could eventually block in both epithelial and stromal cells, the mitogenic effect of catecholamines released during stress, providing a potential additional treatment for breast cancer patients. Chemists synthesizing adrenergic compounds should consider their action in breast cancer patients.
Keywords: Clonidine, rauwolscine, adrenoceptors, mammary tumor, carcinoma-associated fibroblasts, breast cancer, fibroblast MC4-L4F, Dexmedetomidine, G protein coupled receptors, Dulbecco's modified Eagle's medium
Current Cancer Drug Targets
Title: α2-Adrenoceptors Enhance Cell Proliferation and Mammary Tumor Growth Acting Through both the Stroma and the Tumor Cells
Volume: 11 Issue: 6
Author(s): A. Bruzzone, C. Perez Pinero, P. Rojas, M. Romanato, H. Gass, C. Lanari and I. A. Luthy
Affiliation:
Keywords: Clonidine, rauwolscine, adrenoceptors, mammary tumor, carcinoma-associated fibroblasts, breast cancer, fibroblast MC4-L4F, Dexmedetomidine, G protein coupled receptors, Dulbecco's modified Eagle's medium
Abstract: We have previously described enhanced human breast cancer cell proliferation and mouse mammary tumor growth induced by α2-adrenergic agonists, associated with α2-adrenoceptor (α2-AR) expression in epithelial cells. The aim of the present work was to assess if stromal fibroblasts can contribute to this effect. α2-AR expression was assessed by immunocytochemistry and immunohistochemistry, cell proliferation by [3H]- Thymidine incorporation and tumor growth by measuring with caliper. All tested mouse and human fibroblasts expressed at least two α2-AR subtypes and α2-adrenergic agonists enhanced fibroblast proliferation. In vivo, the α2-adrenergic agonist clonidine significantly enhanced tumor growth. The α2- adrenergic antagonist rauwolscine reversed this effect, but when administered alone, significantly inhibited tumor growth. Clonidine significantly stimulated cell proliferation in the epithelial-enriched fraction, the cancer associated fibroblastenriched fraction and the co-culture of both fractions in primary cultures from both tumors (IBH-4 and IBH-6). Rauwolscine reversed clonidine stimulation in every fraction. However, when incubated alone, the inhibitory effect was observed in fractions from IBH-4 tumors but not from IBH-6 tumors. These experiments show that fibroblasts from tumor stroma are also influenced by α2-adrenergic compounds through the α2-ARs expressed in these cells. Moreover, the α2-adrenergic antagonist rauwolscine could eventually block in both epithelial and stromal cells, the mitogenic effect of catecholamines released during stress, providing a potential additional treatment for breast cancer patients. Chemists synthesizing adrenergic compounds should consider their action in breast cancer patients.
Export Options
About this article
Cite this article as:
Bruzzone A., Perez Pinero C., Rojas P., Romanato M., Gass H., Lanari C. and A. Luthy I., α2-Adrenoceptors Enhance Cell Proliferation and Mammary Tumor Growth Acting Through both the Stroma and the Tumor Cells, Current Cancer Drug Targets 2011; 11 (6) . https://dx.doi.org/10.2174/156800911796191051
DOI https://dx.doi.org/10.2174/156800911796191051 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Association Studies: An Information Content Perspective
Current Genomics The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Biologic Drugs in Crohn's Disease and Ulcerative Colitis: Safety Profile
Current Drug Safety Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Decreased Serum Adiponectin Level Affected Clinical Pathological Characteristics of Patients with Gastric Cancer
Current Proteomics Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology Role of Dietary Xenobiotics-Gene Interactions in Carcinogenesis: Protective Effects of Nutritional Factors
Current Nutrition & Food Science Ultrasound Contrast Imaging in Cancer –Technical Aspects and Prospects
Current Molecular Imaging (Discontinued) Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science NPY and Receptors in Immune and Inflammatory Diseases
Current Topics in Medicinal Chemistry Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric Population
Current Radiopharmaceuticals Sentinel Node Imaging
Current Medical Imaging Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery The Role of Chinese Herbs and Acupuncture on the Inflammation Reaction After Cerebral Ischemia
Current Pharmaceutical Design The Role of HLA Promoters in Autoimmunity
Current Pharmaceutical Design Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets Inhibition of Tumor Cells Proliferation and Migration by the Flavonoid Furin Inhibitor Isolated From Oroxylum indicum
Current Medicinal Chemistry Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
Current Cancer Drug Targets